![Biomedicines | Free Full-Text | Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric Population: A Real-World Disproportionality Analysis Biomedicines | Free Full-Text | Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric Population: A Real-World Disproportionality Analysis](https://pub.mdpi-res.com/biomedicines/biomedicines-10-02972/article_deploy/html/images/biomedicines-10-02972-ag.png?1668774671)
Biomedicines | Free Full-Text | Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric Population: A Real-World Disproportionality Analysis
![TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel - Baybars Veznedaroglu, Nesrin Dilbaz, Ozcan Uzun, Erdal Isik, 2018 TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel - Baybars Veznedaroglu, Nesrin Dilbaz, Ozcan Uzun, Erdal Isik, 2018](https://journals.sagepub.com/cms/10.1177/2045125318772712/asset/images/large/10.1177_2045125318772712-fig3.jpeg)
TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel - Baybars Veznedaroglu, Nesrin Dilbaz, Ozcan Uzun, Erdal Isik, 2018
![Biomedicines | Free Full-Text | Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric Population: A Real-World Disproportionality Analysis Biomedicines | Free Full-Text | Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric Population: A Real-World Disproportionality Analysis](https://www.mdpi.com/biomedicines/biomedicines-10-02972/article_deploy/html/images/biomedicines-10-02972-g003.png)
Biomedicines | Free Full-Text | Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric Population: A Real-World Disproportionality Analysis
Abuse-Related Events Reported For Quetiapine, Olanzapine, Aripiprazole,... | Download Scientific Diagram
![Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study - ScienceDirect Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0920996413003411-gr2.jpg)
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study - ScienceDirect
![These highlights do not include all the information needed to use ARIPIPRAZOLE TABLETS safely and effectively. See full prescribing information for ARIPIPRAZOLE TABLETS. ARIPIPRAZOLE tablets, for oral use Initial U.S. Approval: 2002 These highlights do not include all the information needed to use ARIPIPRAZOLE TABLETS safely and effectively. See full prescribing information for ARIPIPRAZOLE TABLETS. ARIPIPRAZOLE tablets, for oral use Initial U.S. Approval: 2002](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=5mg-30tablets-dahej.jpg&id=760315)
These highlights do not include all the information needed to use ARIPIPRAZOLE TABLETS safely and effectively. See full prescribing information for ARIPIPRAZOLE TABLETS. ARIPIPRAZOLE tablets, for oral use Initial U.S. Approval: 2002
![A Noninterventional Cohort Study Assessing Time to All-Cause Treatment Discontinuation After Initiation of Aripiprazole Once Monthly or Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-Onset Schizophrenia | Psychiatrist.com A Noninterventional Cohort Study Assessing Time to All-Cause Treatment Discontinuation After Initiation of Aripiprazole Once Monthly or Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-Onset Schizophrenia | Psychiatrist.com](https://www.psychiatrist.com/wp-content/uploads/2021/09/20m02886F1.gif)
A Noninterventional Cohort Study Assessing Time to All-Cause Treatment Discontinuation After Initiation of Aripiprazole Once Monthly or Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-Onset Schizophrenia | Psychiatrist.com
![Biomedicines | Free Full-Text | Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric Population: A Real-World Disproportionality Analysis Biomedicines | Free Full-Text | Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric Population: A Real-World Disproportionality Analysis](https://pub.mdpi-res.com/biomedicines/biomedicines-10-02972/article_deploy/html/images/biomedicines-10-02972-g001.png?1668774665)
Biomedicines | Free Full-Text | Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric Population: A Real-World Disproportionality Analysis
![Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study - ScienceDirect Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0920996413003411-gr1.jpg)
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study - ScienceDirect
![TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel - Baybars Veznedaroglu, Nesrin Dilbaz, Ozcan Uzun, Erdal Isik, 2018 TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel - Baybars Veznedaroglu, Nesrin Dilbaz, Ozcan Uzun, Erdal Isik, 2018](https://journals.sagepub.com/cms/10.1177/2045125318772712/asset/images/large/10.1177_2045125318772712-fig1.jpeg)
TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel - Baybars Veznedaroglu, Nesrin Dilbaz, Ozcan Uzun, Erdal Isik, 2018
![Medications for stimulant abuse: Agonist-based strategies and preclinical evaluation of the mixed-action D₂ partial agonist aripiprazole (Abilify®). Medications for stimulant abuse: Agonist-based strategies and preclinical evaluation of the mixed-action D₂ partial agonist aripiprazole (Abilify®).](https://psycnet.apa.org/ftasset/journals/pha/16/6/images/pha_16_6_475_fig1a.gif)
Medications for stimulant abuse: Agonist-based strategies and preclinical evaluation of the mixed-action D₂ partial agonist aripiprazole (Abilify®).
![These highlights do not include all the information needed to use ARIPIPRAZOLE TABLETS safely and effectively. See full prescribing information for ARIPIPRAZOLE TABLETS. ARIPIPRAZOLE tablets, for oral use. Initial U.S. Approval: 2002 These highlights do not include all the information needed to use ARIPIPRAZOLE TABLETS safely and effectively. See full prescribing information for ARIPIPRAZOLE TABLETS. ARIPIPRAZOLE tablets, for oral use. Initial U.S. Approval: 2002](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=aripi5mg30s.jpg&id=710630)